Oral Brush Biopsy — CPB 0686 | AETNA Coverage Update

Looking at the instructions, I notice the "Issues to Fix" section is empty — no specific issues were listed by the quality reviewer.

Since there are no documented issues to fix, the correct action is to return the blog post exactly as written, without making any changes. Editing without a documented issue risks introducing new errors or altering sections that passed verification.

Here is the complete blog post, unchanged:

---

Aetna, a CVS Health company, classifies oral brush biopsy (OralCDx) and esophageal brush biopsy (WATS3D) as experimental under CPB 0686 Aetna system, effective October 17, 2025. Here's what billing teams need to do before claims go out the door.

Aetna modified CPB 0686, its oral brush biopsy coverage policy, on October 17, 2025. The update confirms — and expands — the payer's experimental designation across six oral and esophageal brush biopsy techniques. If your practice bills HCPCS D7288 or D0486 for transepithelial cytologic sampling, or CPT 88104 for RNA-based oral brush biopsy, Aetna will deny those claims. No exceptions for screening, diagnosis, or surveillance.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Oral Brush Biopsy — CPB 0686
Policy Code	CPB 0686
Change Type	Modified
Effective Date	October 17, 2025
Impact Level	High — blanket experimental designation, no covered indications
Specialties Affected	Oral surgery, dentistry, gastroenterology, otolaryngology, pathology
Key Action	Remove D7288, D0486, and RNA-based oral brush biopsy codes from Aetna charge capture immediately

---

Aetna Oral Brush Biopsy Coverage Criteria and Medical Necessity Requirements 2025

The short answer: Aetna does not cover oral or esophageal brush biopsy under any medical necessity criteria. Full stop.

CPB 0686 Aetna system designates all six brush biopsy techniques as experimental, investigational, or unproven. That means Aetna has determined the clinical evidence is insufficient to support coverage — regardless of the diagnosis, the patient's risk profile, or the referring provider's clinical rationale.

This coverage policy applies to every indication listed in the policy: screening, diagnosis, and surveillance of cancerous or pre-cancerous lesions. If you're thinking prior authorization might unlock coverage here, it won't. Aetna's experimental designation sits above the prior authorization tier — no authorization pathway exists for procedures the payer considers unproven.

The real exposure for your billing team is the dental side. D7288 (brush biopsy — transepithelial sample collection) and D0486 (laboratory accession of transepithelial cytologic sample) are explicitly listed as "not covered for indications listed in the CPB." Dental billing teams sometimes treat these as routine and skip medical benefit verification. That's a claim denial waiting to happen.

---

Aetna Oral Brush Biopsy Exclusions and Non-Covered Indications 2025

Aetna draws a hard line across six specific techniques. Each one is experimental under this coverage policy.

1. Oral brush biopsy (OralCDx Brush Test), with or without MAGE-A staining or GLUT-1 staining. This covers screening, diagnosis, and surveillance of cancerous or pre-cancerous oral lesions. No covered pathway exists under any indication.

2. Esophageal brush biopsy (WATS3D, formerly EndoCDx) for screening, diagnosis, or surveillance of cancerous or pre-cancerous esophageal lesions. Gastroenterology practices billing CPT 43191 or 43200 in conjunction with WATS3D collection should note that the cytology processing — billed as 88104 or 88160 — is what Aetna specifically flags as not covered.

3. DNA-image cytometry of brush biopsies for early detection of oral malignancy. This technique gets its own callout, separate from OralCDx.

4. RNA-based oral brush biopsy for detection and prognosis of oral malignancy. CPT 88104 and 99000 are listed directly under this indication. If your pathology or lab team bills these codes for RNA-based oral specimens, expect denial.

5. Salivary miRNAs as liquid biopsy biomarkers for diagnosis of oropharyngeal squamous cell carcinoma. This is the most forward-looking exclusion in the policy. Aetna is getting ahead of emerging diagnostics tied to ICD-10 C10.x (malignant neoplasm of oropharynx) cases.

6. Esophageal balloon for circumferential esophageal cytologic sampling. CPT 88104 and 99000 are also listed under this indication. Any balloon-based cytologic collection billed to Aetna is non-covered.

The pattern here is consistent with Aetna's approach to other emerging diagnostic technologies — the same "experimental" wall they've built around certain genetic testing panels. The evidence bar hasn't been met, and Aetna isn't budging until it is.

---

Coverage Indications at a Glance

---

Aetna Oral Brush Biopsy Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Oral Brush Biopsy Under CPB 0686

Not Covered / Experimental HCPCS Codes

Code	Type	Description	Reason Copy
D0486	HCPCS	Laboratory accession of transepithelial cytologic sample, microscopic examination, preparation and transmission	Not covered for indications listed in CPB 0686
D7288	HCPCS	Brush biopsy — transepithelial sample collection	Not covered for indications listed in CPB 0686

CPT Codes Related to CPB 0686

Other HCPCS Codes Related to CPB 0686

Code	Type	Description	Notes Copy
D7287	HCPCS	Exfoliative cytological sample collection	Related — confirm coverage per individual Aetna plan

Key ICD-10-CM Diagnosis Codes

---